Osteoarthritis Structure Claim May Be Separable From Symptom Change - FDA
This article was originally published in The Gray Sheet
An osteoarthritis (OA) labeling claim for slowing of structural deterioration may be separable from claims for improvement in patient symptoms, FDA says in a revised July 15 draft guidance.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.